Opthea Ltd
ASX:OPT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.6
1.155
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
OPT
stock under the Base Case scenario is
0.23
AUD.
Compared to the current market price of 0.6 AUD,
Opthea Ltd
is
Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Opthea Ltd.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Opthea’s lead asset, OPT-302, is heavily reliant on successful Phase III trials in wet AMD; any negative clinical data or regulatory delays could derail the company’s primary growth driver and drain resources.
The company’s pipeline remains narrowly focused on retinal diseases, providing limited diversification; a single setback in OPT-302’s path to commercialization could disproportionately impact Opthea’s valuation and future prospects.
Ongoing development expenses and the likelihood of additional capital raises heighten the risk of shareholder dilution, especially as the firm invests substantially in late-stage clinical trials without parallel revenue streams to offset costs.
OPT-302 has shown encouraging data in earlier clinical stages and, if Phase III results confirm superior efficacy, could tap into the multi-billion-dollar wet AMD market and drive significant revenue growth.
A successful pairing of OPT-302 with existing anti-VEGF treatments may enable Opthea to position the therapy as a differentiator in a competitive market, potentially boosting both market share and adoption rates by physicians.
Opthea’s ongoing collaborations and strong intellectual property protections around VEGF-C/D inhibition could secure a durable competitive edge and improve bargaining positions in future partnerships or licensing deals.
Revenue & Expenses Breakdown
Opthea Ltd
Balance Sheet Decomposition
Opthea Ltd
| Current Assets | 56.8m |
| Cash & Short-Term Investments | 48.4m |
| Receivables | 7.6m |
| Other Current Assets | 750k |
| Current Liabilities | 257.9m |
| Accounts Payable | 9.7m |
| Accrued Liabilities | 1.1m |
| Other Current Liabilities | 247m |
Free Cash Flow Analysis
Opthea Ltd
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Opthea Ltd
|
Revenue
|
25k
USD
|
|
Operating Expenses
|
-155.9m
USD
|
|
Operating Income
|
-155.9m
USD
|
|
Other Expenses
|
-6.9m
USD
|
|
Net Income
|
-162.8m
USD
|
OPT Profitability Score
Profitability Due Diligence
Opthea Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Opthea Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
OPT Solvency Score
Solvency Due Diligence
Opthea Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Opthea Ltd's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OPT Price Targets Summary
Opthea Ltd
Dividends
Current shareholder yield for
OPT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
OPT
stock under the Base Case scenario is
0.23
AUD.
Compared to the current market price of 0.6 AUD,
Opthea Ltd
is
Overvalued by 61%.